{"id":"https://openalex.org/W2434837205","doi":"https://doi.org/10.1111/bjh.14181","title":"Phase Ib trial of the PI 3K/ mTOR inhibitor voxtalisib ( SAR 245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B\u2010cell malignancies","display_name":"Phase Ib trial of the PI 3K/ mTOR inhibitor voxtalisib ( SAR 245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B\u2010cell malignancies","publication_year":2016,"publication_date":"2016-06-13","ids":{"openalex":"https://openalex.org/W2434837205","doi":"https://doi.org/10.1111/bjh.14181","mag":"2434837205","pmid":"https://pubmed.ncbi.nlm.nih.gov/27293194"},"language":"en","primary_location":{"id":"doi:10.1111/bjh.14181","doi":"https://doi.org/10.1111/bjh.14181","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bjh.14181","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.14181","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.14181","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059854479","display_name":"Farrukh Tauseef Awan","orcid":"https://orcid.org/0000-0003-1813-9812","observed_orcids":["https://orcid.org/0000-0003-1813-9812"]},"institutions":[{"id":"https://openalex.org/I2799885155","display_name":"The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","ror":"https://ror.org/028t46f04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Farrukh T. Awan","raw_affiliation_strings":["The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA","institution_ids":["https://openalex.org/I2799885155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037169725","display_name":"Lia Gore","orcid":"https://orcid.org/0000-0002-2546-4616","observed_orcids":["https://orcid.org/0000-0002-2546-4616"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lia Gore","raw_affiliation_strings":["Developmental Therapeutics Program, University of Colorado Comprehensive Cancer Center, Aurora, CO, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Developmental Therapeutics Program, University of Colorado Comprehensive Cancer Center, Aurora, CO, USA","institution_ids":["https://openalex.org/I4210134151"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042870819","display_name":"Lei Gao","orcid":"https://orcid.org/0000-0003-3916-6641","observed_orcids":["https://orcid.org/0000-0003-3916-6641","https://orcid.org/0009-0003-5113-2820","https://orcid.org/0009-0004-7541-4029"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lei Gao","raw_affiliation_strings":["Sanofi, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102727672","display_name":"Jyoti Sharma","orcid":"https://orcid.org/0000-0001-6344-3085","observed_orcids":["https://orcid.org/0000-0001-6344-3085"]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jyoti Sharma","raw_affiliation_strings":["Sanofi, Bridgewater, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Bridgewater, NJ, USA","institution_ids":["https://openalex.org/I4210111804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011428941","display_name":"Joanne J. Lager","orcid":"https://orcid.org/0000-0001-9104-1040","observed_orcids":["https://orcid.org/0000-0001-9104-1040"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joanne Lager","raw_affiliation_strings":["Sanofi, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005850190","display_name":"Luciano J. Costa","orcid":"https://orcid.org/0000-0001-5362-2469","observed_orcids":["https://orcid.org/0000-0001-5362-2469"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Luciano J. Costa","raw_affiliation_strings":["University of Alabama, Birmingham, AL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama, Birmingham, AL, USA","institution_ids":["https://openalex.org/I32389192"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5059854479"],"corresponding_institution_ids":["https://openalex.org/I2799885155"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":null,"fwci":2.4198,"has_fulltext":true,"cited_by_count":15,"citation_normalized_percentile":{"value":0.87582281,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"175","issue":"1","first_page":"55","last_page":"65"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.8442000150680542,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.8442000150680542,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.13920000195503235,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.009200000204145908,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pi3k-mtor-inhibitors","display_name":"PI3K/mTOR inhibitors","score":0.9369999766349792},{"id":"https://openalex.org/keywords/relapsed-or-refractory-b-cell-malignancies","display_name":"relapsed or refractory B-cell malignancies","score":0.949999988079071},{"id":"https://openalex.org/keywords/indolent-non-hodgkin-lymphoma","display_name":"indolent non-Hodgkin lymphoma","score":0.9259999990463257},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":1.0},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9929999709129333},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9639999866485596},{"id":"https://openalex.org/keywords/bendamustine","display_name":"bendamustine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/chemoimmunotherapy","display_name":"chemoimmunotherapy","score":0.953000009059906},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8640000224113464},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8809999823570251},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8529999852180481},{"id":"https://openalex.org/keywords/antitumour-activity","display_name":"antitumour activity","score":0.6019999980926514}],"concepts":[{"id":"https://openalex.org/C2781442060","wikidata":"https://www.wikidata.org/wiki/Q425745","display_name":"Bendamustine","level":4,"score":0.8859559297561646},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.870442807674408},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.8587303161621094},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6675133109092712},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.6577908992767334},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6131279468536377},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5399373769760132},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.5241615772247314},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4690110385417938},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4533500075340271},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4147909879684448},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40829819440841675},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3456902503967285},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.22389119863510132}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000069461","descriptor_name":"Bendamustine Hydrochloride","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000081082","descriptor_name":"Phosphoinositide-3 Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011810","descriptor_name":"Quinoxalines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015448","descriptor_name":"Leukemia, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015448","descriptor_name":"Leukemia, B-Cell","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015448","descriptor_name":"Leukemia, B-Cell","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D015448","descriptor_name":"Leukemia, B-Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D016393","descriptor_name":"Lymphoma, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016393","descriptor_name":"Lymphoma, B-Cell","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016393","descriptor_name":"Lymphoma, B-Cell","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D016393","descriptor_name":"Lymphoma, B-Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019233","descriptor_name":"Retreatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/bjh.14181","doi":"https://doi.org/10.1111/bjh.14181","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bjh.14181","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.14181","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:27293194","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27293194","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of haematology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1111/bjh.14181","doi":"https://doi.org/10.1111/bjh.14181","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bjh.14181","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.14181","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.800000011920929}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2434837205.pdf","grobid_xml":"https://content.openalex.org/works/W2434837205.grobid-xml"},"referenced_works_count":49,"referenced_works":["https://openalex.org/W206701898","https://openalex.org/W1529496601","https://openalex.org/W1954989283","https://openalex.org/W1980497534","https://openalex.org/W1981711832","https://openalex.org/W1991611038","https://openalex.org/W2006546916","https://openalex.org/W2006771504","https://openalex.org/W2017518118","https://openalex.org/W2019874087","https://openalex.org/W2022948980","https://openalex.org/W2031885687","https://openalex.org/W2034623756","https://openalex.org/W2042258092","https://openalex.org/W2050064417","https://openalex.org/W2054917860","https://openalex.org/W2055987368","https://openalex.org/W2066404900","https://openalex.org/W2066564017","https://openalex.org/W2067257663","https://openalex.org/W2070073293","https://openalex.org/W2070487917","https://openalex.org/W2071341510","https://openalex.org/W2080551472","https://openalex.org/W2080942943","https://openalex.org/W2082748100","https://openalex.org/W2095447519","https://openalex.org/W2103334409","https://openalex.org/W2105549867","https://openalex.org/W2106120093","https://openalex.org/W2109439031","https://openalex.org/W2118126216","https://openalex.org/W2124138175","https://openalex.org/W2125357652","https://openalex.org/W2126390772","https://openalex.org/W2127063807","https://openalex.org/W2131826846","https://openalex.org/W2133201432","https://openalex.org/W2134861285","https://openalex.org/W2142099365","https://openalex.org/W2151010413","https://openalex.org/W2154911534","https://openalex.org/W2167197826","https://openalex.org/W2168750246","https://openalex.org/W2276310429","https://openalex.org/W2296290430","https://openalex.org/W2527638889","https://openalex.org/W2580412387","https://openalex.org/W4242290472"],"related_works":["https://openalex.org/W2792557374","https://openalex.org/W1956543993","https://openalex.org/W2607479181","https://openalex.org/W2071341510","https://openalex.org/W2899848123","https://openalex.org/W3174706344","https://openalex.org/W2932994187","https://openalex.org/W1929743028","https://openalex.org/W3097001535","https://openalex.org/W2794337296"],"abstract_inverted_index":{"This":[0],"phase":[1,12],"Ib,":[2],"dose-escalation":[3,83],"study":[4],"investigated":[5],"the":[6,23],"maximum":[7],"tolerated":[8],"dose":[9,14],"(MTD),":[10],"recommended":[11],"II":[13],"(RP2D),":[15],"safety,":[16],"pharmacokinetics":[17],"(PK)":[18],"and":[19,29,66,72,90,133,149,174,192],"preliminary":[20],"efficacy":[21],"of":[22,32,74,101,118],"pan-class":[24],"I":[25],"phosphoinositide":[26],"3-kinase":[27],"(PI3K)":[28],"mechanistic":[30],"target":[31],"rapamycin":[33],"(mTOR)":[34],"inhibitor":[35],"voxtalisib":[36,75,102],"[30":[37],"or":[38,49,56,107,163,185,198],"50":[39,110],"mg":[40,111],"twice":[41],"daily":[42],"(BID)],":[43],"in":[44,54,103,181,196],"combination":[45,104,182],"with":[46,105,161,183],"rituximab":[47,50,106,162,184],"(voxtalisib+rituximab)":[48],"plus":[51],"bendamustine":[52],"(voxtalisib+rituximab+bendamustine),":[53],"relapsed":[55,197],"refractory":[57,199],"indolent":[58],"B-cell":[59,200],"non-Hodgkin":[60],"lymphoma":[61,65],"(NHL),":[62],"mantle":[63],"cell":[64],"chronic":[67],"lymphocytic":[68],"leukaemia":[69],"(CLL).":[70],"MTD":[71],"RP2D":[73,100],"were":[76,93,97,126,142,156],"determined":[77],"using":[78],"a":[79,116],"3":[80,82],"+":[81],"design.":[84],"Adverse":[85],"events":[86],"(AEs),":[87],"plasma":[88],"PK":[89,154],"disease":[91],"response":[92,173],"recorded.":[94],"Thirty-seven":[95],"patients":[96,114],"enrolled.":[98],"The":[99,122,136],"rituximab+bendamustine":[108],"was":[109],"BID.":[112],"Four":[113],"experienced":[115],"total":[117],"five":[119],"dose-limiting":[120],"toxicities.":[121],"most":[123,137],"frequent":[124,138],"AEs":[125,141],"nausea":[127],"(45\u00b79%),":[128],"fatigue":[129],"(37\u00b78%)":[130],"headache":[131],"(32\u00b74%)":[132],"pyrexia":[134],"(32\u00b74%).":[135],"grade":[139],"\u22653":[140],"neutropenia":[143,151],"(27\u00b70%),":[144],"thrombocytopenia":[145],"(24\u00b73%),":[146],"anaemia":[147],"(16\u00b72%)":[148],"febrile":[150],"(10\u00b78%).":[152],"Voxtalisib":[153],"parameters":[155],"not":[157],"affected":[158],"by":[159],"co-administration":[160],"rituximab+bendamustine.":[164],"Of":[165],"35":[166],"efficacy-evaluable":[167],"patients,":[168],"four":[169],"(11\u00b74%)":[170],"achieved":[171,177],"complete":[172],"13":[175],"(37\u00b71%)":[176],"partial":[178],"response.":[179],"Voxtalisib,":[180],"rituximab+bendamustine,":[186],"demonstrated":[187],"an":[188],"acceptable":[189],"safety":[190],"profile":[191],"encouraging":[193],"anti-tumour":[194],"activity":[195],"malignancies.":[201]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}